Invasive epithelial ovarian cancer survival by histotype and disease stage

Journal of the National Cancer Institute

Volumn 111, Issue 1, 2019, Pages

  Peres, Lauren C ^a   Cushing Haugen, Kara L ^b   Köbel, Martin ^c   Harris, Holly R ^b   Berchuck, Andrew ^d   Rossing, Mary Anne ^b   Schildkraut, Joellen M ^a   Doherty, Jennifer A ^b,e  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALASKA NATIVE; AMERICAN; ARTICLE; ASIAN; BRENNER TUMOR; CANCER CLASSIFICATION; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CARCINOSARCOMA; CAUSE SPECIFIC SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL OUTCOME; COLLOID CARCINOMA; ENDOMETRIOID CARCINOMA; ETHNICITY; FEMALE; HISPANIC; HISTOLOGY; HISTOTYPE; HUMAN; INDIAN; INVASIVE CARCINOMA; MIDDLE AGED; MORTALITY RISK; OVARY CARCINOMA; OVERALL SURVIVAL; PACIFIC ISLANDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE; VERY ELDERLY; WORLD HEALTH ORGANIZATION; YOUNG ADULT; ADENOCARCINOMA; CANCER REGISTRY; CYSTADENOCARCINOMA; FOLLOW UP; MORTALITY; OVARY TUMOR; PATHOLOGY; SURVIVAL RATE; TUMOR INVASION;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOSARCOMA; CYSTADENOCARCINOMA, SEROUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; SEER PROGRAM; SURVIVAL RATE; YOUNG ADULT;

EID: 85060176593     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djy071     Document Type: Article

References (55)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30.
2. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013;10(4): 211-224.
3. Engel J, Eckel R, Schubert-Fritschle G, et al. Moderate progress for ovarian cancer in the last 20 years: Prolongation of survival, but no improvement in the cure rate. Eur J Cancer. 2002;38(18):2435-2445.
4. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol. 2002;20(5):1248-1259.
5. Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26-31.
6. Brun JL, Feyler A, Chêne G, Saurel J, Brun G, Hocké C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol. 2000;78:21-27.
7. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: Changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol. 2003;189(4):1120-1127.
8. Kosary CL. Figo stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: An analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994;10(1):31-46.
9. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008;109:370-376.
10. Jemal A, Ward EM, Johnson CJ, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst. 2017;109(9):1-22.
11. Fuh KC, Shin JY, Kapp DS, et al. Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. Gynecol Oncol. 2015; 136(3):491-497.
12. McGuire V, Jesser C, Whittemore AS. Survival among US women with invasive epithelial ovarian cancer. Gynecol Oncol. 2002;84(3):399-403.
13. Park HK, Ruterbusch JJ, Cote ML. Recent trends in ovarian cancer incidence and relative survival in the United States by race/ethnicity and histologic subtypes. Cancer Epidemiol Biomarkers Prev. 2017;26(10):1511-1518.
14. Soslow RA. Histologic subtypes of ovarian carcinoma. Int J Gynecol Pathol. 2008;27:161-174.
15. Vang R, Shih I-M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16(5):267-282.
16. Kobel M, Kalloger S, Baker P, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: A transcanadian study. Am J Surg Pathol. 2010;34(7): 984-993.
17. Kö bel M, Rahimi K, Rambau PF, et al. An immunohistochemical algorithm for ovarian carcinoma typing. Int J Gynecol Pathol. 2016;35(5):430-441.
18. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. Lyon: IARC; 2014.
19. National Cancer Institute. Overview of the SEER program. https://seer.cancer. gov/about/overview.html. Accessed August 17, 2017.
20. Surveillance Epidemiology and End Results (SEER) Program. SEER Stat Database: Incidence-SEER 18 Regs Research Data, Nov 2016 Sub (2000-2014) Katrina/Rita Population Adjustment-Linked To County Attributes-Total US, 1969-2015 Counties, National Cancer Institute, DCCPS, Surveillance Research Program. Released April 2017, based on November 2016 submission.
21. Fritz A, Percy C, Jack A, et al., eds. International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health Organization; 2000.
22. Young JLJ, Roffers SD, Ries LAG, Fritz AG, Hurlburt AA, eds. SEER Summary Staging Manual-2000: Codes and Coding Instructions. NIH Pub. No. 01-4969. Bethesda, MD: National Institute of Health; 2001. https://seer.cancer.gov/ tools/ssm/breast-femgen.pdf. Accessed August 17, 2017.
23. Clarke BA, Gilks B. Ovarian carcinoma: Recent developments in classification of tumour histological subtype. Can J Pathol. 2011:33-42.
24. Rambau PF, McIntyre JB, Taylor J, et al. Morphologic reproducibility, genotyping, and immunohistochemical profiling do not support a category of seromucinous carcinoma of the ovary. Am J Surg Pathol. 2017;41(5):685-695.
25. Cannioto RA, Trabert B, Poole EM, Schildkraut JM. Ovarian cancer epidemiology in the era of collaborative team science. Cancer Causes Control. 2017;28(5): 487-495.
26. Surveillance Research Program, National Cancer Institute SEER∗Stat software, version 8.3.4. seer.cancer.gov/seerstat.
27. Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004;40(15):2307-2316.
28. Howlader N, Ries LAG, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst. 2010;102(20):1584-1598.
29. Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004. Cancer Epidemiol Biomarkers Prev. 2009;18(1):132-139.
30. Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013;24(suppl 10):x16-x21.
31. Makar AP, Baekelandt M, Tropé CG, Kristensen GB. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 1995;56(2):175-180.
32. Winter WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2007;25(24): 3621-3627.
33. MacKay HJ, Brady MF, Oza AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(6):945-952.
34. Akahira J, Yoshikawa H, Shimizu Y, et al. Prognostic factors of stage IV epithelial ovarian cancer: A multicenter retrospective study. Gynecol Oncol. 2001; 81:398-403.
35. Chan J, Fuh K, Shin J, et al. The treatment and outcomes of early-stage epithelial ovarian cancer: Have we made any progress? Br J Cancer. 2008;98(7): 1191-1196.
36. Schiavone MB, Herzog TJ, Lewin SN, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205(5): 480.e1-480.e8.
37. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996;60: 412-417.
38. Mizuno M, Kikkawa F, Shibata K, et al. Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol. 2006; 94:138-143.
39. Motzer RJ, Jonasch E, Agarwal N, et al. Ovarian cancer, version 2. 2014 featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2014;12(2): 175-181.
40. Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment. J Clin Oncol. 2004;22(6):1040-1044.
41. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183-203.
42. Pectasides D, Pectasides E, Psyrri A, Economopoulos T. Treatment issues in clear cell carcinoma of the ovary: A different entity? Oncologist. 2006;11:1089-1094.
43. Del Carmen MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: A review of the literature. Gynecol Oncol. 2012;125(1):271-277.
44. Hamilton CA, Miller A, Casablanca Y, et al. Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol. 2018;148(2):275-280.
45. Hoppenot C, Eckert MA, Tienda SM, Lengyel E. Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol. 2018;148(1):204-212.
46. Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of long-term survivors of epithelial ovarian cancer. Obstet Gynecol. 2015;126(3): 491-497.
47. Dao F, Schlappe BA, Tseng J, et al. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol Oncol. 2016;141(2):260-263.
48. McCluggage WG. Morphological subtypes of ovarian carcinoma: A review with emphasis on new developments and pathogenesis. Pathology. 2011; 43(5):420-432.
49. Zaino RJ, Brady MF, Lele SM, Michael H, Greer B, Bookman MA. Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: A Gynecologic Oncology Group study. Cancer. 2011;117(3):554-562.
50. Herzog TJ, Pothuri B. Ovarian cancer: A focus on management of recurrent disease. Nat Clin Pr Oncol. 2006;3(11):604-611.
51. Smith Sehdev AE, Hutchins GM. Problems with proper completion and accuracy of the cause-of-death statement. Arch Intern Med. 2001;161(2):277-284.
52. Percy C, Stanek E, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health. 1981;71(3):242-250.
53. German RR, Fink AK, Heron M, et al. The accuracy of cancer mortality statistics based on death certificates in the United States. Cancer Epidemiol. 2011; 35(2):126-131.
54. Gilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 2008;39(8):1239-1251.
55. Kommoss S, Gilks CB, du Bois A, Kommoss F. Ovarian carcinoma diagnosis: The clinical impact of 15 years of change. Br J Cancer. 2016;115(8): 993-999.